• Oncology
  • Exited

Epizyme, Inc. (NASDAQ: EPZM) discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule drugs to inhibit the oncogene. The company has two histone methyltransferase (HMT) inhibitors in clinical development. EPZ-5676, a DOT1L HMT inhibitor, is in Phase 1 for acute leukemias with genetic alterations of the MLL gene; and EPZ-6438, an EZH2 HMT inhibitor, is in Phase 1/2 for a genetically defined subtype of non-Hodgkin lymphoma and solid tumors. The Company has partnerships with Celgene, Eisai, and GSK.